Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: dutton: we are raising our price target to $0.90 per share

The present Q ends Feb 29.. Results will not be released until April...So if PTSC desires, they could bury this Qs MMP licenses until then... as well as any J2+ settlement numbers...

regards

Share
New Message
Please login to post a reply